Beiträge zum Thema Advertorial

06. 10. 2014

FDA designates Ariad Pharmaceuticals' lung cancer drug AP26113 as breakthrough therapy

Ariad Pharmaceuticals announced Thursday that the FDA granted breakthrough therapy status for its experimental tyrosine kinase inhibitor (TKI) AP26113 to treat patients with anaplastic lymphoma kinase positive (ALK+), metastatic non-small-cell lung cancer (NSCLC) who are resistant to Pfizer's Xalkori (crizotinib).
LOGIN

Login

Passwort vergessen?